Bay City Capital
Investment Details
Investor Type
Private Investment Firm
Asset Class Focus
Venture Capital, Private Equity
Stage Focus
Seed, Early Stage, Growth, Late Stage, Pre-IPO, Buyout, Turnaround, Distressed
Geographical Focus
United States, Switzerland
Industries Focus
- Life Sciences
- Healthcare Services
- Pharmaceuticals
- Medical Devices
- Diagnostics
- Biotechnology
- Consumer Health
- Medical Technology
- Healthcare Equipment
- Nutrition
- Healthcare IT
- Agribusiness
- Healthcare Supplies
- Healthcare Distribution
- Healthcare Facilities
Investment Size:
1,000,000 to 50,000,000 USD
Investor Details Founded: 1997
Established in 1997, Bay City Capital is a global life sciences investment firm with offices in the United States and Switzerland. The firm specializes in venture capital and private equity investments, focusing on a diversified strategy that spans seed stage to public companies, including innovation, restructuring opportunities, and growth investing. Bay City Capital has managed five venture capital funds with $1.3 billion in capital commitments and has invested in over 100 companies worldwide.
The firm's investment team brings a wealth of experience across all areas of the life sciences industry. Nearly all of their partners have been with the firm for 12 years or more, supported by over 20 investment professionals, distinguished advisers, and scientific advisory board members. Bay City Capital's portfolio includes companies in biotechnology, pharmaceuticals, medical devices, healthcare services, diagnostics, and agribusiness sectors.
Bay City Capital's strategy involves identifying and supporting innovative companies that have the potential to make significant impacts in the life sciences sector. Their approach includes providing capital, strategic guidance, and operational support to foster growth and value creation. The firm's extensive network and deep industry knowledge enable them to effectively navigate the complexities of the life sciences landscape, driving success for their portfolio companies.
Requirements
- Innovative life sciences companies with high growth potential
- Strong management teams
- Clear value proposition in their respective markets
- Ability to scale operations effectively
- Alignment with Bay City Capital's investment strategy and focus areas
Contact
[Official Website Hidden]
[LinkedIn Profile Hidden]
[HQ Location Hidden]
[Email Hidden]
[Contact Number Hidden]
Portfolio Companies
- Dermira
- Bridge Medicines
- Accriva
- Cydan
- Nevro
- Synchronicity
- MGL-3196
- Vtesse
- Werfen
- GF Xinde
Claim this Investor
Are you an official representative of Bay City Capital?
Claim this investor to update information, manage your profile, and get a verified seal.
Claim